Wu Yifang

This profile gathers the share dealings of Wu Yifang in Everest Medicines Ltd., where the filings describe the role as chief executive. We count 12 filings; the first trade dates from 10 October 2025 and the latest from 11 September 2026.

No open-market sale appears; the market trades are 12 purchases worth €7.4M. The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2026, the count stands at 10 purchases and no sales.

A typical purchase (the median) is worth €45k. Measured against the company's value, the median purchase equals 0.0034% of market capitalisation, across 9 purchases where it is known. Of 11 purchases, 5 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The newest entry dates from 14 September 2026: an open-market purchase of €24k, in Everest Medicines Ltd. Between a trade and the moment it shows up on HKEX, the median delay is 2 days. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from HKEX. Past trades are no guide to future returns.